- Avanir Pharmaceuticals (AVNR) ramps higher in the post-session after saying it's entered into an exclusive, multi-year agreement with Merck (MRK) to co-promote MRK's type 2 diabetes therapies Januvia and the sitagliptin family of products in the U.S.
- Terms of the deal were not disclosed.
- Shares +9.6% AH.
Avanir Pharmaceuticals inks co-promotion deal with Merck on Januvia
Aug 12 2013, 16:20 ET